Document is current
Any future updates will be listed below
-
Authors
Nakahata, Misaki https://orcid.org/0000-0002-0100-2863
Tanaka-Mizuno, Sachiko https://orcid.org/0000-0003-0671-5376
Yamaguchi, Fumitaka https://orcid.org/0009-0007-3449-7376
Takeuchi, Masato https://orcid.org/0000-0002-2990-2687
Kawakami, Koji https://orcid.org/0000-0002-7477-4071
- License Information
-
More Information
Article History
Received: 19 March 2023
Accepted: 25 June 2023
First Online: 8 July 2023
Declarations
:
: Koji Kawakami receives concurrent income from JMDC, Inc. and has received research funds from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Mitsubishi Corporation, and Real-World Data Co., Ltd.; consulting fees from LEBER Inc., JMDC Inc., Shin Nippon Biomedical Laboratories Ltd., and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems, Inc.; and honoraria from Mitsubishi Corporation, Pharma Business Academy, and Toppan Inc.
: This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (R3101). Since all data were anonymized, informed consent from the patients was not required. All procedures were conducted according to the Declaration of Helsinki. In addition, all procedures performed in studies involving human participants were following the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
